Violeta Sánchez

7.5k citations

59 papers · 3.8k indexed · 2 hit papers · h-index 28

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism

Papers in

Oncology 40
- HER2/EGFR in Cancer Research 19
- Cancer Immunotherapy and Biomarkers 12
- Cancer Cells and Metastasis 7
- Cancer-related Molecular Pathways 6
Immunology 16
- Immunotherapy and Immune Responses 6

Co-authors: Carlos L. Arteaga Justin M. Balko Melinda E. Sanders Rebecca S. Cook Cammie Rinehart Anindita Chakrabarty María G. Kuba Paula I. González-Ericsson
Journals: Cancer Research (15 papers)Clinical Cancer Research (7 papers)Proceedings of the National Academy of Sciences (4 papers)Breast Cancer Research (3 papers)Journal of Clinical Investigation (2 papers)
Partner nations: United States Australia Peru

In The Last Decade

Violeta Sánchez

54 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation 2017 · 479 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Cell Metabolism
2013 Journal of Clinical Investigation

Peers

Countries citing papers authored by Violeta Sánchez

Since Specialization

Citations

This map shows the geographic impact of Violeta Sánchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Violeta Sánchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Violeta Sánchez more than expected).

Fields of papers citing papers by Violeta Sánchez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Violeta Sánchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Violeta Sánchez. The network helps show where Violeta Sánchez may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Violeta Sánchez, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Violeta Sánchez Line = papers co-authored together Violeta Sánchez links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer Clinical Cancer Research ·Paula I. González-Ericsson, Nisha Unni, Komal Jhaveri, Erica Stringer-Reasor, Qi Liu, Yu Wang, Violeta Sánchez, Hyeok-Jun Kang, Melinda E. Sanders, Brian D. Lehmann, Justin M. Balko, Ben Ho Park, Brent N. Rexer, Ingrid A. Mayer, Carlos L. Arteaga	2025	0
2	NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer Cancer Discovery ·Brandie C. Taylor, Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, Ludovic Varrin, Susan R. Opalenik, Ann Hanna, Laura Bottega, Luc Van Kaer, Henry Gómez, Claudine Isaacs, Tarah J. Ballinger, Cesar A. Santa‐Maria, Payal D. Shah, Elizabeth Claire Dees, Brian D. Lehmann, Vandana G. Abramson, Jennifer A. Pietenpol, Justin M. Balko	2023	31
3	Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance Journal for ImmunoTherapy of Cancer ·Jamaal L. James, Brandie C. Taylor, Margaret L. Axelrod, Xiaopeng Sun, George Ch. Pflug, Paula I. González-Ericsson, Yu Wang, Violeta Sánchez, Catherine C. Fahey, Melinda E. Sanders, Yaomin Xu, Emily Hodges, Douglas B. Johnson, Justin M. Balko	2023	16
4	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer Clinical Cancer Research ·Paula I. González-Ericsson, María Begoña Notario Pérez, Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng, Na Luo, Henry Gómez, Violeta Sánchez, Melinda E. Sanders, Lajos Pusztai, Emanuel Petricoin, Kim Blenman, Justin M. Balko, (unknown)	2021	54
5	MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC JCI Insight ·Derek A. Franklin, Joe T. Sharick, Paula I. González-Ericsson, Violeta Sánchez, Phillip T. Dean, Susan R. Opalenik, Stefano Cairo, Jean-Gabriel Judde, Michael T. Lewis, Jenny C. Chang, Melinda E. Sanders, Rebecca S. Cook, Melissa C. Skala, Jennifer Bordeaux, В В Пяткин, Christine Vaupel, Gary Geiss, Douglas Hinerfeld, Justin M. Balko	2020	25
6	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations Molecular Cancer Research ·Brian D. Lehmann, Timothy M. Shaver, Douglas B. Johnson, Zhu Li, Paula I. González-Ericsson, Violeta Sánchez, Yu Shyr, Melinda E. Sanders, Jennifer A. Pietenpol	2019	11
7	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer Clinical Cancer Research ·Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. González-Ericsson, Violeta Sánchez, Kimberly N. Johnson, Richard G. Abramson, Sheau‐Chiann Chen, Yu Shyr, Carlos L. Arteaga, Antonio C. Wolff, Jennifer A. Pietenpol	2019	113
8	Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival Cancer Research ·Thomas A. Werfel, Shan Wang, Meredith A. Jackson, Taylor E. Kavanaugh, Meghan M. Joly, Linus Lee, Donna J. Hicks, Violeta Sánchez, Paula I. González-Ericsson, Kameron V. Kilchrist, tosihiko kimura, Samantha M. Sarett, Dana M. Brantley‐Sieders, Rebecca S. Cook, Craig L. Duvall	2018	54
9	Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers Cancer Research ·David L. Elion, Max E. Jacobson, Donna J. Hicks, Bushra Rahman, Violeta Sánchez, Paula I. González-Ericsson, Olga Fedorova, Anna Marie Pyle, John T. Wilson, Rebecca S. Cook	2018	133
10	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer Cancer Research ·Valerie M. Jansen, Neil E. Bhola, Joshua A. Bauer, Luigi Formisano, Kyung‐min Lee, Katherine E. Hutchinson, Agnieszka K. Witkiewicz, Preston D. Moore, Mónica V. Estrada, Violeta Sánchez, Paula I. González-Ericsson, Melinda E. Sanders, Paula R. Pohlmann, Michael J. Pishvaian, Marie Arietta, Teresa C. Dugger, Wenyi Wei, Erik S. Knudsen, Carlos L. Arteaga	2017	171
11	Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis Breast Cancer Research ·Meghan M. Joly, Michelle M. Williams, Donna J. Hicks, Bayley A. Jones, Violeta Sánchez, Christian D. Young, Dos D. Sarbassov, William J. Muller, Dana M. Brantley‐Sieders, Rebecca S. Cook	2017	56
12	Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade Molecular Cancer Research ·Michelle M. Williams, Linus Lee, Donna J. Hicks, Meghan M. Joly, David L. Elion, Bushra Rahman, 朴寅星, Violeta Sánchez, Justin M. Balko, Thomas Stricker, Mónica V. Estrada, Rebecca S. Cook	2016	41
13	mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis PLoS Genetics ·Meghan M. Morrison, Christian D. Young, Shan Wang, Tammy Sobolik, Violeta Sánchez, Donna J. Hicks, Rebecca S. Cook, Dana M. Brantley‐Sieders	2015	37
14	Conditional Loss of ErbB3 Delays Mammary Gland Hyperplasia Induced by Mutant PIK3CA without Affecting Mammary Tumor Latency, Gene Expression, or Signaling Cancer Research ·Christian D. Young, Adam D. Pfefferle, Philip Owens, María G. Kuba, Brent N. Rexer, Justin M. Balko, Violeta Sánchez, Hailing Cheng, Charles M. Perou, Jean J. Zhao, Rebecca S. Cook, Carlos L. Arteaga	2013	20
15	HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation Cancer Research ·David Vaught, Jamie C. Stanford, Christian D. Young, Donna J. Hicks, Megumi Nukui, Cammie Rinehart, Violeta Sánchez, John G. Koland, William J. Muller, Carlos L. Arteaga, Rebecca S. Cook	2012	104
16	A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer Cancer Research ·Emily M. Fox, Todd W. Miller, Justin M. Balko, María G. Kuba, Violeta Sánchez, R. A. Smith, Shuying Liu, Ana M. González-Angulo, Gordon B. Mills, Fei Ye, Yu Shyr, H. Charles Manning, Elizabeth Buck, Carlos L. Arteaga	2011	131
17	ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis Cancer Research ·Rebecca S. Cook, Joan T. Garrett, Violeta Sánchez, Jamie C. Stanford, Christian D. Young, Anindita Chakrabarty, Cammie Rinehart, Yixian Zhang, Yaming Wu, Lee M. Greenberger, Ivan D. Horak, Carlos L. Arteaga	2011	64
18	Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase Proceedings of the National Academy of Sciences ·Joan T. Garrett, Maria G. Olivares, Cammie Rinehart, Nara De Matos Granja-Ingram, Violeta Sánchez, Anindita Chakrabarty, Bhuvanesh Dave, Rebecca S. Cook, William Pao, Farida, H. Charles Manning, Jenny C. Chang, Carlos L. Arteaga	2011	359
19	Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells Clinical Cancer Research ·Todd W. Miller, James T. Forbes, Chirayu Shah, Shelby K. Wyatt, H. Charles Manning, Maria G. Olivares, Violeta Sánchez, Teresa C. Dugger, Nara de Matos Granja, Archana Narasanna, Rebecca S. Cook, J. Phillip Kennedy, Craig W. Lindsley, Carlos L. Arteaga	2009	99
20	Terapia de resincronización cardíaca: punto de vista del cardiólogo clínico Juan F. Delgado, L. Alonso Pulpón, Miguel Ángel Broc Cavero, Violeta Sánchez	2005	1

About Violeta Sánchez

Violeta Sánchez is a scholar working on Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Cancer Research, having authored 59 papers that have together received 3.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (19 papers), PI3K/AKT/mTOR signaling in cancer (12 papers), Cancer Immunotherapy and Biomarkers (12 papers), Cancer Cells and Metastasis (7 papers), Immunotherapy and Immune Responses (6 papers), Cancer-related Molecular Pathways (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Cell death mechanisms and regulation (4 papers). The work is most often cited by research in Oncology (2.1k citations), Cancer Research (840 citations), Molecular Biology (2.1k citations), Immunology (601 citations) and Genetics (294 citations). Violeta Sánchez has collaborated with scholars based in United States, Australia and Peru. Frequent co-authors include Carlos L. Arteaga, Justin M. Balko, Melinda E. Sanders, Rebecca S. Cook, Cammie Rinehart, Anindita Chakrabarty, María G. Kuba, Paula I. González-Ericsson, Jamie C. Stanford and Teresa C. Dugger. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Proceedings of the National Academy of Sciences, Breast Cancer Research and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact